Diakonos Oncology
Diakonos Oncology is a clinical-stage biotechnology company focused on developing groundbreaking immunotherapy treatments for difficult-to-treat cancers. With FDA Fast Track designation, they are advancing innovative dendritic cell vaccines, such as DOC1021, to improve patient outcomes in cancers like glioblastoma and pancreatic adenocarcinoma. Their research leverages a novel understanding of dendritic cell mechanisms to activate powerful immune responses, aiming to address unmet medical needs in oncology.
Industries
Nr. of Employees
small (1-50)
Diakonos Oncology
Products
Autologous double-loaded dendritic cell immunotherapy
An investigational autologous dendritic cell therapy produced by loading patient-derived tumor mRNA intracellularly and tumor lysate extracellularly to present overlapping MHC class I and II epitopes and induce Th1/cytotoxic T-cell responses for solid tumors.
Autologous double-loaded dendritic cell immunotherapy
An investigational autologous dendritic cell therapy produced by loading patient-derived tumor mRNA intracellularly and tumor lysate extracellularly to present overlapping MHC class I and II epitopes and induce Th1/cytotoxic T-cell responses for solid tumors.
Services
Clinical trial conduct and site partnerships
Design and execution of Phase 1 and randomized multi-center Phase 2 oncology trials at academic and clinical partner sites.
Expanded access program coordination
Evaluation and potential initiation of expanded access pathways for patients who do not qualify for clinical trials of investigational cell therapy.
Research collaborations and translational studies
Collaborative preclinical and translational research with academic institutions to advance mechanistic understanding and validate therapeutic approaches.
Clinical trial conduct and site partnerships
Design and execution of Phase 1 and randomized multi-center Phase 2 oncology trials at academic and clinical partner sites.
Expanded access program coordination
Evaluation and potential initiation of expanded access pathways for patients who do not qualify for clinical trials of investigational cell therapy.
Research collaborations and translational studies
Collaborative preclinical and translational research with academic institutions to advance mechanistic understanding and validate therapeutic approaches.
Expertise Areas
- Dendritic cell vaccine development
- Autologous cell therapy manufacturing and processing
- Oncology clinical trial design and execution
- Immunology of Th1 polarization and T-cell activation
Key Technologies
- Dendritic cell vaccine platform
- Autologous tumor mRNA isolation and amplification
- Electroporation-mediated mRNA delivery
- Tumor lysate preparation for ex vivo antigen presentation